Rates of certain dermatologic and neuropsychological side effects may differ across oral contraceptive formulations, according to an analysis of U.S. adverse-event and prescribing data suggests.
Researchers analyzed adverse-event reports from the U.S. Food and Drug Administration Adverse Event Reporting System alongside prescription data from the Medical Expenditure Panel Survey. They compared reported rates of acne, migraine, anxiety, and depression among users of commonly prescribed oral contraceptive formulations between 2016 and 2020.
The analysis used ethinyl estradiol/norethindrone as the reference formulation, as it represents one of the earliest and most widely prescribed combined oral contraceptives. The investigators compared reported side-effect rates across several formulations containing different progestins, including levonorgestrel, desogestrel, norgestimate, and drospirenone, as well as a norethindrone-only pill.
Higher relative rates of acne were reported with several formulations compared with the reference medication. In particular, pills containing drospirenone, levonorgestrel, or norgestimate were associated with increased reporting of acne. Drospirenone-containing contraceptives were also linked to higher reported rates of migraine and depression in the analysis.
Anxiety reports also varied across formulations. Higher rates were observed with levonorgestrel- and desogestrel-containing pills, while lower rates were reported among users of norethindrone-only pills compared with the reference formulation.
Overall, reported depression rates were low across most contraceptive formulations, although drospirenone-containing pills showed higher reporting compared with the reference medication. The investigators noted that interpretation of these patterns may be complicated by prescribing trends, including the possibility that certain formulations are preferentially prescribed to patients with specific baseline conditions.
The authors noted that oral contraceptives are widely used and generally well tolerated, but dermatologic and mood-related symptoms remain among the side effects most commonly reported by patients. Because individual formulations differ in their progestin components and pharmacologic properties, these variations may influence reported side-effect profiles.
Because the analysis relied on post-marketing adverse-event reports, the findings reflect patterns in reported symptoms rather than confirmed causal relationships. The databases also lacked detailed clinical information, preventing adjustment for factors such as patient demographics, dosing differences, or underlying health conditions.
The authors suggest that improved understanding of formulation-specific side-effect patterns may help clinicians tailor contraceptive selection for patients with dermatologic or mental health comorbidities.
The authors reported no conflicts of interest.
